Classical NF-κB pathway is responsible for APOBEC3B expression in cancer cells

Biochemical and Biophysical Research Communications

Volumn 478, Issue 3, 2016, Pages 1466-1471

  Maruyama, Wataru ^a   Shirakawa, Kotaro ^a   Matsui, Hiroyuki ^a   Matsumoto, Tadahiko ^a   Yamazaki, Hiroyuki ^a   Sarca, Anamaria D ^a   Kazuma, Yasuhiro ^a   Kobayashi, Masayuki ^a   Shindo, Keisuke ^a   Takaori Kondo, Akifumi ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

APOBEC3B; I B kinase (IKK); NF kappa B (NF B); Phorbol myristate acetate (PMA); Protein kinase C (PKC)

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN P50; SYNAPTOTAGMIN I; APOBEC3B PROTEIN, HUMAN; CYTIDINE DEAMINASE; MINOR HISTOCOMPATIBILITY ANTIGEN; PROTEIN KINASE C;

ARTICLE; CANCER CELL; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; GEL MOBILITY SHIFT ASSAY; HUMAN; HUMAN CELL; LUCIFERASE ASSAY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; TRANSCRIPTION REGULATION; BINDING SITE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HELA CELL LINE; MCF-7 CELL LINE; METABOLISM; PROMOTER REGION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

BINDING SITES; CELL LINE, TUMOR; CYTIDINE DEAMINASE; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HUMANS; MCF-7 CELLS; MINOR HISTOCOMPATIBILITY ANTIGENS; NF-KAPPA B; PROMOTER REGIONS, GENETIC; PROTEIN KINASE C; RNA, MESSENGER; SIGNAL TRANSDUCTION; TETRADECANOYLPHORBOL ACETATE;

EID: 84994021910     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2016.08.148     Document Type: Article

References (26)

1. [1] Alexandrov, L.B., Nik-Zainal, S., Wedge, D.C., Aparicio, S.A., Behjati, S., Biankin, A.V., Bignell, G.R., Bolli, N., Borg, A., Borresen-Dale, A.L., Boyault, S., Burkhardt, B., Butler, A.P., Caldas, C., Davies, H.R., Desmedt, C., Eils, R., Eyfjord, J.E., Foekens, J.A., Greaves, M., Hosoda, F., Hutter, B., Ilicic, T., Imbeaud, S., Imielinski, M., Jager, N., Jones, D.T., Jones, D., Knappskog, S., Kool, M., Lakhani, S.R., Lopez-Otin, C., Martin, S., Munshi, N.C., Nakamura, H., Northcott, P.A., Pajic, M., Papaemmanuil, E., Paradiso, A., Pearson, J.V., Puente, X.S., Raine, K., Ramakrishna, M., Richardson, A.L., Richter, J., Rosenstiel, P., Schlesner, M., Schumacher, T.N., Span, P.N., Teague, J.W., Totoki, Y., Tutt, A.N., Valdes-Mas, R., van Buuren, M.M., van 't Veer, L., Vincent-Salomon, A., Waddell, N., Yates, L.R., Australian Pancreatic Cancer Genome, I., Consortium, I.B.C., Consortium, I.M.-S., PedBrain, I., Zucman-Rossi, J., Futreal, P.A., McDermott, U., Lichter, P., Meyerson, M., Grimmond, S.M., Siebert, R., Campo, E., Shibata, T., Pfister, S.M., Campbell, P.J., Stratton, M.R., Signatures of mutational processes in human cancer. Nature 500 (2013), 415–421.
2. [2] Walker, B.A., Wardell, C.P., Murison, A., Boyle, E.M., Begum, D.B., Dahir, N.M., Proszek, P.Z., Melchor, L., Pawlyn, C., Kaiser, M.F., Johnson, D.C., Qiang, Y.W., Jones, J.R., Cairns, D.A., Gregory, W.M., Owen, R.G., Cook, G., Drayson, M.T., Jackson, G.H., Davies, F.E., Morgan, G.J., APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma. Nat. Commun., 6, 2015, 6997.
3. [3] Burns, M.B., Lackey, L., Carpenter, M.A., Rathore, A., Land, A.M., Leonard, B., Refsland, E.W., Kotandeniya, D., Tretyakova, N., Nikas, J.B., Yee, D., Temiz, N.A., Donohue, D.E., McDougle, R.M., Brown, W.L., Law, E.K., Harris, R.S., APOBEC3B is an enzymatic source of mutation in breast cancer. Nature 494 (2013), 366–370.
4. [4] Leonard, B., Hart, S.N., Burns, M.B., Carpenter, M.A., Temiz, N.A., Rathore, A., Vogel, R.I., Nikas, J.B., Law, E.K., Brown, W.L., Li, Y., Zhang, Y., Maurer, M.J., Oberg, A.L., Cunningham, J.M., Shridhar, V., Bell, D.A., April, C., Bentley, D., Bibikova, M., Cheetham, R.K., Fan, J.B., Grocock, R., Humphray, S., Kingsbury, Z., Peden, J., Chien, J., Swisher, E.M., Hartmann, L.C., Kalli, K.R., Goode, E.L., Sicotte, H., Kaufmann, S.H., Harris, R.S., APOBEC3B upregulation and genomic mutation patterns in serous ovarian carcinoma. Cancer Res. 73 (2013), 7222–7231.
5. [5] Shinohara, M., Io, K., Shindo, K., Matsui, M., Sakamoto, T., Tada, K., Kobayashi, M., Kadowaki, N., Takaori-Kondo, A., APOBEC3B can impair genomic stability by inducing base substitutions in genomic DNA in human cells. Sci. Rep., 2, 2012, 806.
6. [6] Cescon, D.W., Haibe-Kains, B., Mak, T.W., APOBEC3B expression in breast cancer reflects cellular proliferation, while a deletion polymorphism is associated with immune activation. Proc. Natl. Acad. Sci. U. S. A. 112 (2015), 2841–2846.
7. [7] Tsuboi, M., Yamane, A., Horiguchi, J., Yokobori, T., Kawabata-Iwakawa, R., Yoshiyama, S., Rokudai, S., Odawara, H., Tokiniwa, H., Oyama, T., Takeyoshi, I., Nishiyama, M., APOBEC3B high expression status is associated with aggressive phenotype in Japanese breast cancers. Breast Cancer 23 (2016), 780–788.
8. [8] Yan, S., He, F., Gao, B., Wu, H., Li, M., Huang, L., Liang, J., Wu, Q., Li, Y., Increased APOBEC3B predicts worse outcomes in lung Cancer: a comprehensive retrospective study. J. Cancer 7 (2016), 618–625.
9. [9] Mori, S., Takeuchi, T., Ishii, Y., Kukimoto, I., Identification of APOBEC3B promoter elements responsible for activation by human papillomavirus type 16 E6. Biochem. Biophys. Res. Commun. 460 (2015), 555–560.
10. [10] Eychene, A., Rocques, N., Pouponnot, C., A new MAFia in cancer. Nat. Rev. Cancer 8 (2008), 683–693.
11. [11] Karin, M., NF-kappaB as a critical link between inflammation and cancer. Cold Spring Harb. Perspect. Biol., 1, 2009, a000141.
12. [12] DiDonato, J.A., Mercurio, F., Karin, M., NF-kappaB and the link between inflammation and cancer. Immunol. Rev. 246 (2012), 379–400.
13. [13] Jost, P.J., Ruland, J., Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood 109 (2007), 2700–2707.
14. [14] Prasad, S., Ravindran, J., Aggarwal, B.B., NF-kappaB and cancer: how intimate is this relationship. Mol. Cell Biochem. 336 (2010), 25–37.
15. [15] Endo, Y., Marusawa, H., Kinoshita, K., Morisawa, T., Sakurai, T., Okazaki, I.M., Watashi, K., Shimotohno, K., Honjo, T., Chiba, T., Expression of activation-induced cytidine deaminase in human hepatocytes via NF-kappaB signaling. Oncogene 26 (2007), 5587–5595.
16. [16] Leonard, B., McCann, J.L., Starrett, G.J., Kosyakovsky, L., Luengas, E.M., Molan, A.M., Burns, M.B., McDougle, R.M., Parker, P.J., Brown, W.L., Harris, R.S., The PKC/NF-kappaB signaling pathway induces APOBEC3B expression in multiple human cancers. Cancer Res. 75 (2015), 4538–4547.
17. [17] Refsland, E.W., Stenglein, M.D., Shindo, K., Albin, J.S., Brown, W.L., Harris, R.S., Quantitative profiling of the full APOBEC3 mRNA repertoire in lymphocytes and tissues: implications for HIV-1 restriction. Nucleic Acids Res. 38 (2010), 4274–4284.
18. [18] Fischle, W., Dequiedt, F., Hendzel, M.J., Guenther, M.G., Lazar, M.A., Voelter, W., Verdin, E., Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Mol. Cell 9 (2002), 45–57.
19. [19] Mathelier, A., Fornes, O., Arenillas, D.J., Chen, C.Y., Denay, G., Lee, J., Shi, W., Shyr, C., Tan, G., Worsley-Hunt, R., Zhang, A.W., Parcy, F., Lenhard, B., Sandelin, A., Wasserman, W.W., JASPAR 2016: a major expansion and update of the open-access database of transcription factor binding profiles. Nucleic Acids Res. 44 (2016), D110–D115.
20. [20] Wu, D., Wu, P., Zhao, L., Huang, L., Zhang, Z., Zhao, S., Huang, J., NF-kappab expression and outcomes in solid tumors: a systematic review and meta-analysis. Med. Baltim., 94, 2015, e1687.
21. [21] Chaturvedi, M.M., Sung, B., Yadav, V.R., Kannappan, R., Aggarwal, B.B., NF-kappaB addiction and its role in cancer: 'one size does not fit all'. Oncogene 30 (2011), 1615–1630.
22. [22] Demchenko, Y.N., Glebov, O.K., Zingone, A., Keats, J.J., Bergsagel, P.L., Kuehl, W.M., Classical and/or alternative NF-kappaB pathway activation in multiple myeloma. Blood 115 (2010), 3541–3552.
23. [23] Warren, C.J., Xu, T., Guo, K., Griffin, L.M., Westrich, J.A., Lee, D., Lambert, P.F., Santiago, M.L., Pyeon, D., APOBEC3A functions as a restriction factor of human papillomavirus. J. Virol. 89 (2015), 688–702.
24. [24] Verhalen, B., Starrett, G.J., Harris, R.S., Jiang, M., Functional upregulation of the DNA cytosine deaminase APOBEC3B by polyomaviruses. J. Virol. 90 (2016), 6379–6386.
25. [25] James, M.A., Lee, J.H., Klingelhutz, A.J., Human papillomavirus type 16 E6 activates NF-kappaB, induces cIAP-2 expression, and protects against apoptosis in a PDZ binding motif-dependent manner. J. Virol. 80 (2006), 5301–5307.
26. [26] Lucifora, J., Xia, Y., Reisinger, F., Zhang, K., Stadler, D., Cheng, X., Sprinzl, M.F., Koppensteiner, H., Makowska, Z., Volz, T., Remouchamps, C., Chou, W.M., Thasler, W.E., Huser, N., Durantel, D., Liang, T.J., Munk, C., Heim, M.H., Browning, J.L., Dejardin, E., Dandri, M., Schindler, M., Heikenwalder, M., Protzer, U., Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science 343 (2014), 1221–1228.